Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pascal Hendrik Pieter de Jong has a total of 221 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Imaging-guided treatment strategy compared to standard care in at-risk individuals for rheumatoid arthritis: a cost-utility analysis

    by Sterre Bour, Elise Van Mulligen, Lucas Goossens, Pascal Hendrik Pieter de Jong, Annette van der Helm - van Mil, Maureen Rutten-Van Molken

  • Open Access

    Treat-to-target strategies are feasible in elderly-onset rheumatoid arthritis given its reassuring risk–benefit profile

    by Hamit Harun Dag, Marloes G B van Onna, Radboud J E M Dolhain, Pascal H P de Jong

    Objective: To compare 2-year pharmacotherapy needs and adverse events (AEs) profiles between patients with elderly-onset rheumatoid arthritis (EORA) and young-onset RA (YORA) under a treat-to-target (T2T) strategy with a fixed medication protocol. Methods: Data from the treatment in the Rotterdam Early Arthritis cohort trial, a multicentre randomised controlled study, were analysed. Patients with RA (1987/2010 criteria) were classified as EORA (>65 years) or YORA (18–65 years). Disease Activity Score based on 44 swollen and 53 tender joint counts (DAS44) trajectories, active disease and sustained remission were assessed using mixed-effects models. Protocol-guided disease-modifying antirheumatic drug (DMARD) and glucocorticoid (GC) use, difficult-to-treat (D2T) RA prevalence and AEs were evaluated descriptively. Cox proportional hazards models examined time to first biologic (b)DMARD initiation, bDMARD survival and DMARD-free remission. Results: Among 425 patients with RA, 98 (23%) had EORA (mean age 73 years, SD 5) and 327 (77%) had YORA (mean age 48 years, SD 11). Patients with EORA were more often male (50% vs 28%) and had more comorbidities (76% vs 49%). DAS44 trajectories were similar (mean difference 0.03, 95% CI −0.13 to 0.18), but EORA had less often active disease (OR 0.8, 95% CI 0.4 to 1.5) and more often sustained remission (OR 1.5, 95% CI 0.6 to 3.4). bDMARD initiation rate was lower and slower in EORA than YORA (28% vs 38%; HR 0.7, 95% CI 0.4 to 1). First bDMARD survival and GC use were comparable. D2T-RA was rare (EORA 2% vs YORA 6%) and treatment adjustments due to AEs were similar (43% vs 47%). Conclusion: A T2T approach is feasible and effective in EORA, given its reassuring risk-benefit profile, while recognising the need for individualised management.

  • Open Access

    Exploring possibilities towards PeRsonalIsed MEdicine in Rheumatoid Arthritis (PRIMERA): tailored modifications to standard treat-to-target management—a multicentre, randomised, open-label trial

    by Agnes E M Looijen, Hamit Harun Dag, Judith W Heutz, Floris A van Gaalen, Mirjam C Hegeman, Jos H van der Kaap, Lindy-Anne Korswagen, Roos C Padmos, Naghmeh Riyazi, Julia Spierings, et al.

    Objectives: Guidelines for early rheumatoid arthritis (RA) recommend starting methotrexate, with optional glucocorticoid (GC) bridging, followed by treat-to-target intensifications after at least 3 months (routine care). Given RA’s heterogeneity, we evaluated a stratified treat-to-target approach (tailor-made approach) consisting of two modifications to routine care: first-line disease-modifying antirheumatic drug (DMARD) selection stratified by autoantibody status and rapid treatment intensifications guided by early treatment response (within 1 month). Methods: This multicentre, open-label randomised controlled trial included adults with DMARD-naïve RA (2010 American College of Rheumatology/European Alliance of Associations for Rheumatology (EULAR) criteria) who were randomly assigned (1:1) to the tailor-made approach or routine care. Both arms followed a treat-to-target strategy, intensifying every 3–4 months until Disease Activity Score (DAS) ≤2.4. The tailor-made approach started MTX in autoantibody-positive patients and hydroxychloroquine in autoantibody-negative patients, both with intramuscular GC bridging. Additional intensifications at months 1 and 4 were allowed when DAS >2.4, 1 month after DMARD initiation or intensification, enabling treatment escalation before the standard 3-month reassessment. Routine care started MTX with GC bridging regardless of autoantibody status and without extra intensifications. The two primary outcomes were targeted synthetic/biologic (ts/b)DMARD use at 10 months and mean DAS over time; superiority required both to favour the tailor-made approach. Results: In total, 308 included patients were randomised(152 tailor-made; 156 routine care). At 10 months, ts/bDMARD use was 21% in the tailor-made approach vs 17% in routine care (one-sided p=0.20). Mean DAS trajectories were similar (p=0.57). No differences were observed in mean patient-reported outcome measure trajectories or adverse events. Conclusion: Modifying the standard treat-to-target strategy, by stratifying the initial DMARD according to autoantibody status combined with rapidly intensifying therapy based on early treatment response, did not result in superior clinical outcomes. Trial registration number: ISRCTN16170070 .

  • Open Access

    Effect of an Online, Interactive Lifestyle Intervention Program on 12-Month Disease Management Outcomes: Protocol for The Healthy Living in Inflammatory Arthritis (HELIA) Randomized Controlled Trial

    by Kim van Slingerland, Nathalie Wilmsen, Emma Coles, Radboud J E M Dolhain, Pascal H P de Jong

    Background: Innovative disease management strategies have significantly improved clinical outcomes in inflammatory arthritis (IA). Although more than 80% of patients achieve low disease activity (LDA), the disease continues to exert a considerable impact on patients’ lives. For these patients with IA, a lifestyle intervention program may add value by reducing inflammatory activity, potentially alleviating the disease burden and the risk of a flare. Objective: This study aimed to compare 12-month disease management outcomes between patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) with LDA who follow an online, interactive lifestyle intervention program (Leef! met Reuma) and those who receive general nutrition recommendations offered as part of usual care. Methods: The Healthy Living in Inflammatory Arthritis (HELIA) trial is an open-label, randomized controlled clinical trial with the aim of enrolling 200 adult patients diagnosed with RA or PsA according to the American College of Rheumatology or European Alliance of Associations for Rheumatology 2010 criteria, or Classification for Psoriatic Arthritis criteria, respectively. Other inclusion criteria were (1) having LDA defined as Disease Activity Score ≥2.6 and 4 and <16 and (2) stable disease-modifying antirheumatic drug dosages for ≥6 months prior to randomization. Patients are randomized into a lifestyle intervention or general nutrition recommendations using a 1:1 allocation ratio. The lifestyle intervention program consists of a 6-month intensive part, followed by an 18-month aftercare period. During the intensive part, there were 5 online Zoom (Zoom Communications Inc) meetings and 7 coaching sessions. The program focuses on 4 pillars, namely nutrition, exercise, relaxation, and sleep. The prescribed diet resembles the Mediterranean diet, with an emphasis on unprocessed foods. The general nutrition recommendations are based on the Dutch food-based dietary guidelines. The primary objective is the proportional difference in Disease Activity Score and Disease Activity in Psoriatic Arthritis remission and/or successful tapering of disease-modifying antirheumatic drug treatment after 12 months of follow-up. Meeting either criterion is sufficient to qualify for the primary outcome. Additionally, a cost-effectiveness analysis will be conducted using the incremental cost-effectiveness ratio as the outcome. Other secondary objectives include health risk and clinical and patient-reported outcomes over time and at specific time points. Primary and secondary outcomes are analyzed according to an intention-to-treat principle. Results: The trial was registered in the ISRCTN (International Standard Randomised Controlled Trial Number) registry retrospectively after recruitment had begun, due to administrative issues. The authors acknowledge this deviation. Conclusions: A randomized controlled trial is performed to compare the effectiveness of an online, interactive lifestyle intervention program and general nutrition recommendations in patients with IA with LDA from a clinical, patient, and societal point of view. If the intervention is proven effective, it can be applied as a complementary option to current treatment approaches.

  • Open Access

    Effects of biologic and targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) on patient-reported outcome domains in rheumatoid arthritis: a systematic review and network meta-analyses

    by Luuk van Esveld, Marijke van Den Dikkenberg, Nathalie Luurssen-Masurel, Pascal de Jong, Marc Redwart Kok, Tessa Bosch, Mariska Quirina Nikita Hackert, Angelique Weel-Koenders, Deirisa Lopes Barreto, Tjallingius Martijn Kuijper

    Introduction: Evidence from head-to-head comparisons of biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) on patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) is lacking. This systematic review and network meta-analysis (NMA) aims to evaluate the relative effects of b/tsDMARDs on the International Consortium for Health Outcomes Measurement (ICHOM) RA-relevant domains of pain, fatigue, activity limitation, and physical and mental health. Methods: A systematic literature search was conducted using the machine learning tool ASReview. Randomised controlled trials were included that compared DMARDs with placebo or other DMARDs and reported the effects on PROs from the ICHOM standard set for inflammatory arthritis. Random effects NMA were performed on PROs. Results: In total, 99 studies were included, with heterogeneity within comparisons ranging from low to very high (I²=0%–96%). Janus kinase inhibitors (mean difference (MD) Health Assessment Questionnaire: −0.13; 95% CI−0.23 to −0.04) and IL-6 inhibitors (MD: −0.13; 95% CI −0.27 to −0.00) were significantly better at reducing activity limitation than tumour necrosis factor inhibitors. Other significant differences between b/tsDMARD classes were not observed. The surface under the cumulative ranking curve demonstrated that rituximab was overall ranked best among b/tsDMARDs. IL-6 inhibitors ranked highest in the mental health domain (82%). Early RA (<3 years diagnosis) and worse baseline PRO scores were associated with larger improvements of PROs (p<0.05). Conclusions: Despite heterogeneity, the results of this study may help rheumatologists guide selection of b/tsDMARDs, taking into account PROs that are important to the patient or reflect their primary symptoms. Future research should investigate within-class differences between specific b/tsDMARDs and emphasise individualised, PRO-based augmentation within treat-to-target strategies. PROSPERO registration number: CRD42020147514


  • Open Access

    Induction of Cure in Early Arthritis (I CEA): results of a randomised clinical trial to compare three treatment strategies in recent onset undifferentiated arthritis

    by Isabell S Nevins, Joy Ardjuna van der Pol, Lotte Van Ouwerkerk, Gregory S Helmich, Reinhard Bos, Sjoerd M Van Der Kooij, Harald E Vonkeman, Jessica Bijsterbosch, Pascal Hendrik Pieter de Jong, Melek Güler-Yüksel, et al.

    Objectives: To investigate whether in undifferentiated arthritis (UA) it is beneficial to start early treatment with disease-modifying antirheumatic drugs (DMARDs) compared with symptomatic therapy. Methods: The Induction of Cure in Early Arthritis study is a 3-month multicentre single-blinded randomised controlled trial followed by a 9-month observational period. Patients with early DMARD-naïve UA (arthritis ≥2 joints, not fulfilling American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) 2010 Rheumatoid Arthritis criteria) received a glucocorticoid injection (40 mg intra-articular or intramuscular) and were randomised (1:1:1) to a 3-month intervention with (1) non-steroidal anti-inflammatory drugs (NSAIDs) in standard daily dose or (2) methotrexate (MTX) 15 mg/week increased to 25 mg/week or (3) baricitinib 4 mg/day. Primary endpoint was Disease Activity Score (DAS) (44/53 joints) improvement at 3 months. Differences between treatment arms were assessed with analysis of covariance, adjusted for baseline DAS. Results: Patients were randomised to NSAID (n=29), MTX (n=28) or baricitinib (n=28). After 3 months, baricitinib gave a significant improvement in DAS compared with NSAIDs: adjusted mean change in DAS: −0.52 (95% CI −0.93 to −0.11; p=0.01). MTX gave a numerically similar improvement: −0.39 (95% CI −0.84 to 0.06, p=0.09). Although non-significant, at 12 months DAS was lowest in the MTX treatment arm 1.3 (SD 0.7), NSAID 1.6 (SD 0.9), baricitinib 1.7 (SD 0.9), p=0.38. Incidence rates of severe adverse events remained low during the study across all treatment arms. Conclusions: In patients with UA, early DMARD treatment led to greater improvement in disease activity over 3 months compared with NSAIDs, with the improvement for baricitinib reaching statistical significance. Over 12 months, disease activity was not significantly different across treatment arms, with overall favourable outcomes.


  • Open Access

    Drivers of Methotrexate Polyglutamate Concentration in Erythrocytes: Insights from Immune-Mediated Inflammatory Diseases and Pediatric Acute Lymphoblastic Leukemia

    by Janani Sundaresan, Wout J. Hamelink, Renske C. F. Hebing, Maartje van de Meeberg, Montse Janssen Bonás, Inge M. van der Sluis, Pascal H. P. de Jong, Martijn Heymans, Robert de Jonge, Maurits C. F. J. de Rotte, et al.

    Background/Objectives: Methotrexate (MTX) is a cornerstone drug used to treat immune-mediated inflammatory diseases (IMIDs) in low doses (10–30 mg/week), and malignancies in high doses (5000 mg/m2/2 weeks). Its active metabolites, Methotrexate polyglutamates (MTX-PG2–5), quantified in erythrocytes, are associated with efficacy. This study aimed to compare erythrocyte MTX-PG concentrations in patients with IMIDs and pediatric acute lymphoblastic leukemia (ped-ALL) treated with low-dose or high-dose MTX, respectively, and to identify clinical, demographic, and treatment-related factors influencing their concentration. Methods: A total of 567 patients with rheumatoid arthritis, juvenile idiopathic arthritis, Crohn’s disease, sarcoidosis, and ped-ALL were included. Erythrocyte MTX-PG concentration data was collected after 3 months (2.5 months for ped-ALL patients) of MTX-use. Multivariate linear regressing modelling adjusting for age, sex, body mass index (BMI), smoking status, starting MTX dose, route of MTX administration, use of predniso(lo)ne, disease-modifying anti-rheumatic drugs (DMARDs), and folic (or folinic) acid was performed. Results: Intravenous high-dose MTX increased MTX-PG4&5 accumulation. Despite 50-fold higher doses in ped-ALL, MTX-PG2–5sum concentrations were similar to those seen with subcutaneous low-dose MTX used in IMIDs. Age positively influenced MTX-PG concentrations, while DMARD use reduced MTX-PG2–3&5 concentrations. Interestingly, predniso(lo)ne use was associated with higher MTX-PG4&5 concentrations and folic (or folinic) acid with higher MTX-PG3–5 concentrations. Conclusions: This is the first study to compare erythrocyte MTX-PG concentration in low-dose and high-dose patients. Intravenous high-dose MTX administration increased long-chain MTX-PG4&5 concentrations, with MTX-PG2–5sum concentrations similar compared to low-dose subcutaneous MTX use. This study demonstrated that route of administration, age, and concomitant therapies such as DMARDs, predniso(lo)ne, and folic (or folinic) acid significantly influence MTX-PG concentrations.


  • Open Access

    Modified Dixon MRI to detect subclinical inflammation in clinically suspect arthralgia as a risk factor for rheumatoid arthritis development: should we image one or two hands?

    by Daniek van der Kaaij, Stijn Claassen, Hanna W van Steenbergen, Edwin H G Oei, Pascal H P de Jong, Monique Reijnierse, Annette H M van der Helm-Van Mil

    Objectives: MRI-detected subclinical inflammation in clinically suspect arthralgia (CSA) predicts progression to inflammatory arthritis (IA) and rheumatoid arthritis (RA) and is incorporated in EULAR/ACR risk stratification criteria. Conventional MRI is hampered by long scan times, intravenous contrast and high costs, while modified Dixon (mDixon) MRI, with 5 min scan time and no intravenous contrast, is much more feasible. To optimise mDixon MRI utility, we compared bilateral versus unilateral hand analysis for detecting subclinical inflammation. We also studied the distribution of subclinical inflammation in CSA. Methods: 139 patients of the CSA Leiden cohort were included. mDixon MRIs of bilateral wrist and metacarpophalangeal 2–5 joints were scored for subclinical inflammation (synovitis/tenosynovitis/osteitis) using RA MRI scoring. The hand with the most self-reported painful joints was used for unilateral analysis. Patients were followed for ≥6 months, with IA and RA development assessed at 6 months. We compared prognostic performance of bilateral versus unilateral MRI-detected subclinical inflammation. Results: Subclinical inflammation detected on bilateral MRI was more strongly associated with IA development than on unilateral MRI; 4.80 (95% CI 1.09 to 21.11) versus 2.34 (95% CI 0.84 to 6.49). Bilateral analysis resulted in a 25% higher sensitivity and 15% lower specificity, with a net 10% increase in correctly classified patients. Results for RA development were similar, with HRs of 8.17 (95% CI 1.06 to 62.86) versus 3.23 (95% CI 0.98 to 10.66), and 20% higher sensitivity. Subclinical inflammation was unilateral in 52% of patients and scanning one hand would miss a quarter of patients. Conclusion: Bilateral MRI of the hands is preferable to unilateral MRI for detecting subclinical inflammation in CSA, because of its asymmetrical distribution.

  • Open Access

    PeRsonalIsed MEdicine in Rheumatoid Arthritis (PRIMERA) trial: a multicentre, open-label, randomised controlled trial comparing routine care with a tailor-made approach

    by Hamit Harun Dag, Agnes E M Looijen, Harald E Vonkeman, Annemiek Willemze, Lindy-Anne Korswagen, Roos C Padmos, Floris A van Gaalen, Ilja Tchetverikov, Jos H van der Kaap, Josien J Veris-Van Dieren, et al.

    Introduction: Rheumatoid arthritis (RA) is a heterogeneous disease, which current treatment guidelines insufficiently accommodate, as they predominantly emphasise the suppression of disease activity. However, a step towards personalised medicine is preferred to further optimise treatment and requires homogeneous subgroups with similarities in pathophysiological mechanisms and treatment responses. Prior research has already demonstrated notable differences in the pathophysiology of patients with autoantibody-positive and autoantibody-negative RA, as well as differences in treatment responses, which may serve as a strong basis for personalised medicine. Additionally, there is evidence suggesting that an early treatment response is indicative of future courses. Based on these findings, we designed a personalised medicine trial in RA that compares the effectiveness and cost-effectiveness of a tailor-made approach with routine care. Methods and analysis: The PeRsonalIsed Medicine in RA (PRIMERA) trial is a multicentre, open-label, randomised controlled trial that includes 300 adult patients with newly diagnosed, DMARD-naïve RA, according to 2010 American College of Rheumatology/EULAR criteria. Patients are randomised into either routine care or a tailor-made approach. Both management approaches use a treat-to-target strategy, aiming for low disease activity (LDA, Disease Activity Score using 44 joints (DAS) ≤2.4). In routine care, initial treatment consists of methotrexate along with a single intramuscular dose of glucocorticoids (GCs) and treatment can be intensified after 3, 7 and 10 months if LDA is not reached. Conversely, initial treatment in the tailor-made approach depends on the presence of autoantibodies, with patients with autoantibody-positive and autoantibody-negative RA starting with hydroxychloroquine or methotrexate together with a single intramuscular dose of GCs, respectively. Medication intensifications will be allowed at months 1, 3, 4, 7 and 10. Intensifications at months 1 and 4 depend on whether patients have an early sufficient response to GCs and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), respectively. The tailor-made approach is superior to routine care if no more biological DMARDs (bDMARDs) or tsDMARDs are used after 10 months of treatment, while the mean DAS over time is lower. Our primary outcome is the proportional difference in bDMARD or tsDMARD usage after 10 months of treatment between routine care and the tailor-made approach. Secondary outcomes are DAS over time, time to achieve LDA, cost-effectiveness and patient-reported outcome measurements over time. Ethics and dissemination: Ethical approval has been granted by Erasmus MC Medical Ethics Review Committee (MEC-2020-0825). The results will be disseminated through peer-review journals and medical congresses. Trial registration number: NCT16170070 .